HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Afatinib
/ administration & dosage
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antibody-Dependent Cell Cytotoxicity
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Apoptosis
/ drug effects
Breast Neoplasms
/ drug therapy
Cell Proliferation
/ drug effects
Drug Synergism
Female
Humans
Lapatinib
/ administration & dosage
Protein Kinase Inhibitors
/ pharmacology
Quinolines
/ administration & dosage
Receptor, ErbB-2
/ antagonists & inhibitors
Trastuzumab
/ administration & dosage
Tumor Cells, Cultured
Afatinib
Breast cancer
HER2-positive
Lapatinib
Neratinib
erbB2
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
10
05
2018
accepted:
19
07
2018
pubmed:
1
8
2018
medline:
23
2
2020
entrez:
1
8
2018
Statut:
ppublish
Résumé
Despite trastuzumab and pertuzumab improving outcome for patients with HER2-positive metastatic breast cancer, the disease remains fatal for the majority of patients. This study evaluated the anti-proliferative effects of adding anti-HER2 tyrosine kinase inhibitors (TKIs) to trastuzumab and pertuzumab in HER2-positive breast cancer cells. Afatinib was tested alone and in combination with trastuzumab in HER2-positive breast cancer cell lines. TKIs (lapatinib, neratinib, afatinib) combined with trastuzumab and/or pertuzumab were tested in 3 cell lines, with/without amphiregulin and heregulin-1β. Seven of 11 HER2-positive cell lines tested were sensitive to afatinib (IC
Identifiants
pubmed: 30062574
doi: 10.1007/s10637-018-0649-y
pii: 10.1007/s10637-018-0649-y
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Protein Kinase Inhibitors
0
Quinolines
0
Lapatinib
0VUA21238F
Afatinib
41UD74L59M
Receptor, ErbB-2
EC 2.7.10.1
neratinib
JJH94R3PWB
pertuzumab
K16AIQ8CTM
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
441-451Références
Int J Dev Biol. 2011;55(7-9):685-96
pubmed: 22161825
Oncotarget. 2013 Oct;4(10):1592-605
pubmed: 24009064
Lancet Oncol. 2016 Mar;17(3):367-377
pubmed: 26874901
Oncogene. 1997 Sep 18;15(12):1385-94
pubmed: 9333014
Clin Cancer Res. 2007 Aug 15;13(16):4909-19
pubmed: 17699871
J Clin Oncol. 2015 May 10;33(14):1574-83
pubmed: 25779558
Lancet Oncol. 2014 Sep;15(10):1137-46
pubmed: 25130998
Oncologist. 2008 Jun;13(6):620-30
pubmed: 18586917
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
Cancer Res. 2009 Dec 15;69(24):9330-6
pubmed: 19934333
Clin Pharmacokinet. 2013 Dec;52(12):1101-9
pubmed: 23813493
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Invest New Drugs. 2011 Oct;29(5):752-9
pubmed: 20229355
J Pharmacol Exp Ther. 2012 Nov;343(2):342-50
pubmed: 22888144
J Cancer Res Clin Oncol. 2016 Jan;142(1):157-65
pubmed: 26195282
Bioorg Med Chem Lett. 2003 Feb 24;13(4):637-40
pubmed: 12639547
J Med Chem. 2005 Feb 24;48(4):1107-31
pubmed: 15715478
Cancer Res. 2006 Feb 1;66(3):1630-9
pubmed: 16452222
Clin Cancer Res. 2009 Apr 1;15(7):2552-8
pubmed: 19318484
Ann Oncol. 2012 Jul;23(7):1788-95
pubmed: 22056974
Ann Oncol. 2012 Aug;23(8):2204-5
pubmed: 22767587
Breast Cancer Res Treat. 2010 Jul;122(1):35-43
pubmed: 19701706
Mol Cancer Ther. 2010 Jun;9(6):1489-502
pubmed: 20501798
Cancer Res. 2004 Apr 1;64(7):2343-6
pubmed: 15059883
N Engl J Med. 2006 Dec 28;355(26):2733-43
pubmed: 17192538
N Engl J Med. 2016 Jul 7;375(1):11-22
pubmed: 27406346
Breast Cancer Res. 2013;15(5):R85
pubmed: 24044505
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Oncogenesis. 2012 Jul 02;1:e16
pubmed: 23552733